Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Meets Expectations

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Monday. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03), FiscalAI reports. The business had revenue of $35.25 million for the quarter, compared to analyst estimates of $37.50 million. Heron Therapeutics had a negative return on equity of 293.02% and a negative net margin of 22.52%.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $0.37 on Tuesday. The stock’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.67. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49. Heron Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.57. The firm has a market cap of $70.36 million, a price-to-earnings ratio of -1.95 and a beta of 1.65.

Analyst Ratings Changes

Several brokerages have commented on HRTX. HC Wainwright lowered shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, October 15th. Finally, Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $2.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.